In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Seeking Alpha / 3 hours ago 1 Views
In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases
Comments